6 days ago
1
Dmitry Vinogradov
Axsome Therapeutics (NASDAQ:AXSM) has been initiated with Overweight and a $163 price target at Wells Fargo, highlighting optimism for the approval of AXS‑05 in Alzheimer’s disease agitation.
The analysts say that while Axsome’s clinical data package is mixed, the FDA may
English (US) ·